StockNews.com upgraded shares of Akebia Therapeutics (NASDAQ:AKBA - Free Report) from a sell rating to a hold rating in a report released on Tuesday.
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research note on Wednesday, October 23rd.
Read Our Latest Stock Report on AKBA
Akebia Therapeutics Trading Down 0.5 %
Shares of AKBA stock traded down $0.01 on Tuesday, reaching $1.86. The company had a trading volume of 2,016,306 shares, compared to its average volume of 1,906,167. The stock has a market cap of $405.82 million, a PE ratio of -8.09 and a beta of 0.72. The company has a 50-day moving average of $1.90 and a 200-day moving average of $1.52. Akebia Therapeutics has a 12 month low of $0.80 and a 12 month high of $2.48.
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). The company had revenue of $37.43 million for the quarter, compared to analyst estimates of $45.66 million. During the same period in the prior year, the company posted ($0.08) EPS. Sell-side analysts anticipate that Akebia Therapeutics will post -0.24 earnings per share for the current year.
Hedge Funds Weigh In On Akebia Therapeutics
Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in Akebia Therapeutics by 10.9% during the third quarter. JPMorgan Chase & Co. now owns 98,546 shares of the biopharmaceutical company's stock worth $130,000 after purchasing an additional 9,662 shares during the last quarter. Franklin Resources Inc. acquired a new position in shares of Akebia Therapeutics during the 3rd quarter worth about $221,000. Barclays PLC grew its holdings in shares of Akebia Therapeutics by 276.1% in the 3rd quarter. Barclays PLC now owns 273,085 shares of the biopharmaceutical company's stock valued at $360,000 after acquiring an additional 200,482 shares in the last quarter. Geode Capital Management LLC raised its holdings in Akebia Therapeutics by 4.8% during the third quarter. Geode Capital Management LLC now owns 4,754,464 shares of the biopharmaceutical company's stock worth $6,277,000 after acquiring an additional 218,172 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Akebia Therapeutics during the third quarter worth about $58,000. Institutional investors and hedge funds own 33.92% of the company's stock.
About Akebia Therapeutics
(
Get Free Report)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Recommended Stories
Before you consider Akebia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.
While Akebia Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
